Abstract
Is Molecular Characterization Useful for Targeted Therapy Orientation in Patients with Relapsed or Refractory DLBCL Included in Early Phase Clinical Trials?
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have